Months 6 and Beyond: This phase focuses on sustainable management and long-term health improvements, including improved metabolic markers and reduced joint strain
Introductions to Jennifer Killebrew, DNP, APRN, RN, and Nikki Kelton, RN
Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review
Patients who have been on Wegovy or Zepbound through the program would face three options: Pay out of pocket at retail prices (currently $1,000-$1,300 per month) Discontinue the medication , which research suggests leads to significant weight regain Transition to an alternative covered treatment , such as bariatric surgery or other covered medications The STEP 1 extension study showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year
Regulators including the U.S